Correction to: Cerebrospinal fluid amyloid-β 2-42 is decreased in Alzheimer’s, but not in frontotemporal dementia (Journal of Neural Transmission, (2012), 119, 7, (805-813), 10.1007/s00702-012-0801-3);Cerebrospinal fluid amyloid-β 2-42 is decreased in Alzheimer's, but not in frontotemporal dementia

Journal of Neural Transmission

Volumn 119, Issue 7, 2012, Pages 805-813

  Bibl, Mirko ^a,b   Gallus, Marion ^b   Welge, Volker ^b   Esselmann, Hermann ^b   Wolf, Stefanie ^a   Rüther, Eckart ^c   Wiltfang, Jens ^b  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Alzheimer's dementia; Aminoterminally truncated; Amyloid peptides; A 2 42; Cerebrospinal fluid; Frontotemporal dementia

Indexed keywords

AMYLOID BETA PROTEIN[1-38]; AMYLOID BETA PROTEIN[1-42]; AMYLOID BETA PROTEIN[2-42]; GLYCOPROTEIN; UNCLASSIFIED DRUG;

AGE; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; FEMALE; FRONTOTEMPORAL DEMENTIA; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE;

EID: 84863423724     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-018-1914-0     Document Type: Erratum

References (37)

1. Albertini V, Bruno A, Paterlini A, Lista S, Benussi L, Cereda C, Binetti G, Ghidoni R (2010) Optimization protocol for amyloid-β peptides detection in human cerebrospinal fluid using SELDI TOF MS. Proteomics Clin Appl 3:352-357
2. Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B, Blennow K (2001) Evaluation of CSF-tau and CSF-Aβ42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol 58:373-379
3. Bibl M, Esselmann H, Otto M, Lewczuk P, Cepek L, Rüther E, Kornhuber J, Wiltfang (2004) Cerebrospinal fluid (CSF) amyloid beta (Aβ) peptide patterns in Alzheimer's disease (AD) patients and non-demented controls depend on sample pre-treatment: indication of carrier-mediated epitope masking of Aβ peptides. Electrophoresis 25:2912-2918
4. Bibl M, Mollenhauer B, Lewczuk P, Esselmann H, Wolf S, Trenkwalder C, Otto M, Stiens G, Ruther E, Kornhuber J, Wiltfang J (2007a) Validation of amyloid-β peptides in CSF diagnosis of neurodegenerative dementias. Mol Psychiatry 12:671-680
5. Bibl M, Mollenhauer B, Wolf S, Esselmann H, Lewczuk P, Kornhuber J, Wiltfang J (2007b) Reduced CSF carboxyterminally truncated Aβ peptides in frontotemporal lobe degenerations. J Neural Transm 114:621-628
6. Bibl M, Lewczuk P, Esselmann H, Mollenhauer B, Klafki HW, Welge V, Wolf S, Trenkwalder C, Otto M, Kornhuber J, Wiltfang J (2008) CSF amyloid-β 1-38 and 1-42 in FTD and AD: biomarker performance critically depends on the detergent accessible fraction. Proteomics Clin App 2:1548-1556
7. Bibl M, Gallus M, Welge V, Lehmann S, Sparbier K, Esselmann H, Wiltfang J (2011a) Characterization of cerebrospinal fluid aminoterminally truncated and oxidized amyloid-β-peptides. Proteomics Clin Appl (in press)
8. Bibl M, Mollenhauer B, Lewczuk P, Esselmann H, Wolf S, Otto M, Kornhuber J, Rüther E, Wiltfang J (2011b) Cerebrospinal fluid tau, p-tau 181 and amyloid-βl38/40/42 in frontotemporal dementias and primary progressive aphasias. Dement Geriatr Cogn Disord 31:37-44
9. Bibl M., Gallus M, Welge V, Esselmann H, Wiltfang J (2011b) Aminoterminally truncated and oxidized amyloid-β peptides in the cerebrospinal fluid of Alzheimer's dementia patients. J Alzheimers Dis (in press)
10. Blennow K (2004) Cerebrospinal fluid protein biomarkers for Alzheimer's disease. NeuroRx 1:213-225
11. Fagan AM, Mintun M, Mach RH, Lee SY, Dence CS, Shah AR, LaRossa GN, Spinner ML, Klunk WE, Matthis CA, DeKosky ST, Morris JC, Holtzmann DM (2006) Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 59:512-519
12. Gabelle A, Roche S, Gény C, Bennys K, Labauge P, Tholance Y, Quadrio I, Tiers L, Gor B, Boulanghien J, Chaulet C, Vighetto A, Croisile B, Krolak-Salmon P, Perret-Liaudet A, Touchon J, Lehmann S (2011) Decreased sAβPPb, Aβ38, and Aβ40 cerebrospinal fluid levels in frontotemporal dementia. J Alzheimers Dis 26:553-563
13. Galasko D, Marder K (2002) Picking away at frontotemporal dementia. Neurology 58:1585-1586
14. Ghidoni R, Paterlini A, Albertini V, Stoppani E, Binetti G, Fuxe K, Benussi L, Agnati LF (2011) A window into the heterogeneity of human cerebrospinal fluid Aβ peptides. J. Biomed Biotechnol 2011:697036
15. Glenner GG, Wong CW (1984) Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 120:885-890
16. Güntert A, Döbeli H, Bohrmann B (2006) High sensitivity analysis of amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain. Neuroscience 143:461-475
17. Hampel H, Buerger K, Zinkowski R, Teipel SJ, Goernitz A, Andreasen N, Sjoegren M, DeBernardis J, Kerkman D, Ishiguro K, Ohno H, Vanmechelen E, Vanderstichele H, McCulloch C, Möller HJ, Davies P, Blennow K (2004) Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer's disease-a comparative study. Arch Gen Psychiatry 61:95-102
18. Hulstaert F, Blennow K, Ivanoiu A, Schoonderwald HC, Riemenschneider M, De Deyn PP, Bancher C, Cras P, Wiltfang J, Mehta PD, Iqbal K, Pottel H, Vanmechelen E, Vanderstichele H (1999) Improved discrimination of AD-patients using ß-amyloid (1-42) and tau levels in CSF. Neurology 52:1555-1562
19. Larson ME, Lesnè SE (2012) Soluble Aβ oligomer production and toxicity. J Neurochem 120:125-139
20. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34:939-944
21. Motter R, Vigo-Pelfrey C, Kholodenko D, Barbour R, Johnson-Wood K, Galasko D, Chang L, Miller B, Clark C, Green R, Olson D, Southwick P, Wolfert R, Munroe B, Lieberburg I, Seubert P, Schenk D (1995) Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 38:643-648
22. Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, Freedman M, Kertesz A, Robert PH, Albert M, Boone K, Miller BL, Cummings J, Benson DF (1998) Frontotemporal lobar degeneration. A consensus on clinical diagnostic criteria. Neurology 51:1546-1554
23. Portelius E, Westman-Brinkmalm A, Zetterberg H, Blennow K (2006) Determination of beta-amyloid peptide signatures in cerebrospinal fluid using immunoprecipitation-mass spectrometry. J Proteome Res 4:1010-1016
24. Portelius E, Tran AJ, Andreasson U, Persson R, Brinkmalm G, Zetterberg H, Blennow K, Westman-Brinkmalm A (2007) Characterization of amyloid beta peptides in cerebrospinal fluid by an automated immunoprecipitation procedure followed by mass spectrometry. J Proteome Res 11:4433-4439
25. Portelius E, Brinkmalm G, Tran AJ, Zetterberg H, Westman-Brinkmalm A, Blennow K (2009) Identification of novel APP/Aβ isoforms in human cerebrospinal fluid. Neurodegener Dis 6:87-94
26. Riemenschneider M, Wagenpfeil S, Diehl J, Lautenschlager N, Theml T, Heldmann B, Drzezga A, Jahn T, Förstl H, Kurz A (2002) Tau and Aβ42 protein in CSF of patients with frontotemporal degeneration. Neurology 58:1622-1628
27. Schieb H, Weidlich S, Schlechtingen G, Linning P, Jennings G, Gruner M, Wiltfang J, Klafki HW, Knölker HJ (2010) Structural design, solid-phase synthesis and activity of membrane-anchored β-secretase inhibitors on Aβ generation from wild-type and Swedish-mutant APP. Chemistry 16:14412-14423
28. Schieb H, Kratzin H, Jahn O, Möbius W, Rabe S, Staufenbiel M, Wiltfang J, Klafki HW (2011) Beta-amyloid peptide variants in brains and cerebrospinal fluid from amyloid precursor protein (APP) transgenic mice: comparison with human Alzheimer amyloid. J Biol Chem 286:33747-33758
29. Sevalle J, Amoyel A, Robert P, Fournie-Zaluski MC, Roques B, Checler F (2009) Aminopeptidase A contributes to the N-terminal truncation of amyloid β-peptide. J Neurochem 109:248-256
30. 1-42 and GAP-43 in frontotemporal dementia, other types of dementia and normal aging. J Neural Transm 107:563-579
31. Tammer AH, Coia G, Cappai R, Fuller S, Masters CL, Hudson P, Underwood JR (2002) Generation of a recombinant Fab antibody reactive with the Alzheimer's disease related Aβ peptide. Clin Exp Immunol 129:453-463
32. The Working Group on:"Molecular and Biochemical Markers of Alzheimer's Disease" (1998) Consensus report of the Working Group on: "Molecular and Biochemical Markers of Alzheimer's Disease". The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group. Neurobiol Aging 19:109-116
33. Vanderstichele H, De Meyer G, Andreasen N, Kostanjevecki V, Wallin A, Olsson A, Blennow K, Vanmechelen E (2005) Aminotruncated beta-amyloid42 peptides in cerebrospinal fluid and prediction of progression of mild cognitive impairment. Clin Chem 9:1650-1660
34. Welge V, Fiege O, Lewczuk P, Mollenhauer B, Esselmann H, Klafki HW, Wolf S, Trenkwalder C, Otto M, Kornhuber J, Wiltfang J, Bibl M (2009) Combined CSF tau, p-tau181 and amyloid-β 38/40/42 for diagnosing Alzheimer's disease. J Neural Transm 116:203-212
35. Wiltfang J, Esselmann H, Cupers P, Neumann M, Kretzschmar H, Beyermann M, Schleuder D, Jahn H, Rüther E, Kornhuber J, Annaert W, De Strooper B, Saftig P (2001) Elevation of betaamyloid peptide 2-42 in sporadic and familial Alzheimer's disease and its generation in PS1 knockout cells. J Biol Chem 276:42645-42657
36. Wiltfang J, Esselmann H, Bibl M, Smirnov A, Otto M, Paul S, Schmid B, Klafki H-W, Maler M, Dyrks T, Bienert M, Beyermann M, Rüther E, Kornhuber J (2002) Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and patients with chronic neuroinflammation. J Neurochem 81:481-496
37. World Medical Organisation (1996) Declaration of Helsinki. BMJ 313:1407-1431